Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor.
Major histocompatibility complex (MHC) molecules are rare in the healthy brain tissue, but are heavily expressed on microglial cells after inflammatory or neurodegenerative processes. We studied the conditions leading to the induction of MHC class II molecules in microglia by using explant cultures of neonatal rat hippocampus, a model of interacting neuronal networks. Interferon-gamma (IFN-gamma)-dependent MHC class II inducibility in microglia cells was very low, but strongly increased in the hippocampal slices after the blockade of neuronal activity by neurotoxins [tetrodotoxin (TTX), omega-conotoxin] or glutamate antagonists. None of these agents acted directly on isolated microglia cells. We found that neurotrophins modulate microglial MHC class II expression. MHC class II inducibility was enhanced by neutralization of neurotrophins produced locally within the cultured tissues and was inhibited by the addition of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), or neurotrophin-3 (NT3). NGF and, to a lower extent, NT3 acted directly on isolated microglia via the p75 neurotrophin receptor and inhibited MHC class II inducibility as shown by blockade of the p75 neurotrophin receptor with antibodies. Our data suggest that neurotrophins secreted by electrically active neurons control the antigen-presenting potential of microglia cells, and indicate that this effect is mediated partly via the p75 neurotrophin receptor.
Neumann
H
H
Department of Neuroimmunology, Max-Planck Institute of Neurobiology, Am Klopferspitz 18 A, 82152-Martinsried, Germany. hneumann@neuro.mpg.de
Misgeld
T
T
Matsumuro
K
K
Wekerle
H
H
D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002450:Cell Communication / Q000187:drug effects; D002478:Cells, Cultured; D019084:Fluorescent Antibody Technique, Indirect; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis*; D007371:Interferon-gamma / Q000378:metabolism; D017628:Microglia / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D018613:Microscopy, Confocal; D009414:Nerve Growth Factors / Q000494:pharmacology / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D020933:Neurotrophin 3; D010455:Peptides / Q000494:pharmacology; D051381:Rats; D011917:Rats, Inbred Lew; D020800:Receptor, Nerve Growth Factor; D017475:Receptors, Nerve Growth Factor / Q000502:physiology*; D013779:Tetrodotoxin / Q000494:pharmacology; D020866:omega-Conotoxin GVIA
D019208:Brain-Derived Neurotrophic Factor; D002121:Calcium Channel Blockers; D000949:Histocompatibility Antigens Class II; D009414:Nerve Growth Factors; D020933:Neurotrophin 3; D010455:Peptides; D020800:Receptor, Nerve Growth Factor; D017475:Receptors, Nerve Growth Factor; D013779:Tetrodotoxin; D007371:Interferon-gamma; D020866:omega-Conotoxin GVIA